Arsenic exposure is a worldwide health concern associated with an increased risk of lung cancer but arsenic trioxide (AsIII) is also an effective chemotherapeutic agent, Inactivation of ZnT1 or its transcriptional activator MTF1 resulted in considerable AsIII resistance [16]. This evidence concerns the gene MTF1 and lung carcinoma.